Rubius Therapeutics, Inc.
DelistedCIK 1709401fmd_09930KR5NNY88F4FH6QYW1GMJAManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2016 to Dec 31, 2022, 25 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 0 | 0 | 0 |
| Research and development | 8 | 21 | 52 | 112 | 116 | 142 | 96 |
| Total operating expenses | 11 | 43 | 92 | 170 | 166 | 195 | 178 |
| Operating income | (11) | (43) | (92) | (170) | (166) | (195) | (178) |
| Interest expense | 0 | 0 | 0 | 3 | 4 | 6 | 4 |
| Interest and investment income | – | 1 | 5 | 8 | 2 | 0 | 1 |
| Other non-operating income (expense) | (0) | (1) | 2 | 6 | (1) | (2) | (1) |
| Net income | (11) | (44) | (89) | (164) | (168) | (197) | (180) |
| Net income to common shareholders | (12) | (45) | (89) | (163) | – | – | – |